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Abstract  
Transcription of the ribosomal RNA genes (rDNA) by RNA Polymerase I (Pol I) is a 
major control step for ribosome synthesis and is tightly linked to cellular growth. 
However, the question of whether this process is modulated primarily at the level of 
transcription initiation or elongation is controversial. Studies in markedly different 
cell types have identified either initiation or elongation as the major control point. In 
this study, we have re-examined this question in NIH3T3 fibroblasts using a 
combination of metabolic labelling of the 47S rRNA, chromatin immunoprecipitation 
analysis of Pol I and overexpression of the transcription initiation factor Rrn3. Acute 
manipulation of growth factor levels altered rRNA synthesis rates over 8-fold without 
changing Pol I loading onto the rDNA. In fact, robust changes in Pol I loading were 
only observed under conditions where inhibition of rDNA transcription was 
associated with chronic serum starvation or cell cycle arrest. Overexpression of the 
transcription initiation factor Rrn3 increased loading of Pol I on the rDNA but failed 
to enhance rRNA synthesis in either serum starved, serum treated or G0/G1 arrested 
cells. Together these data suggest that transcription elongation is rate limiting for 
rRNA synthesis. We propose that transcription initiation is required for rDNA 
transcription in response to cell cycle cues, whereas elongation controls the dynamic 
range of rRNA synthesis output in response to acute growth factor modulation.  
 
Introduction 
Transcription of the ribosomal RNA (rRNA) genes that encode the precursor of the 
28S, 5.8S and 18S rRNAs is generally considered one of the most fundamental rate- 
limiting steps for the synthesis of ribosomes and therefore growth and proliferation 
[1-5]. Human diploid cells have 400-600 rDNA repeats [6, 7] but only a subset of 
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these genes is transcribed at any given time [8-12]. Modulation of rRNA synthesis 
rates in response to growth factors, stress, and cell cycle cues appears to be controlled 
almost exclusively by changing the activity of a fixed number of  “transcriptionally 
competent genes” rather than epigenetically silencing or reactivating rRNA genes [13, 
14]. Pol I transcription initiation begins with the formation of the preinitiation 
complex (PIC) by the upstream binding factor (UBF) and the TBP-containing 
complex selectively factor (SL-1) at the rDNA promoter [15-19]. The resultant 
UBF/SL-1 complex facilitates recruitment of an initiation competent subpopulation of 
Pol I, defined by the presence of the basal regulatory factors PAF53/PAF49 and Rrn3 
(also called TIF-1A), to form a functional PIC at the rDNA promoters [2, 20-25].  
Rrn3 appears to play an essential role in integrating extracellular cues with 
transcription initiation. Phosphorylation of Rrn3 by kinases linked to nutrient or 
energy availability, mitogen activation, stress and cell cycle cues modulate its 
transcriptional initiation activity. These observations led to the proposal that 
transcription initiation via modulation of Rrn3 activity is the major rate-limiting step 
for rRNA synthesis in mammalian cells [22, 26-31]. This model is supported by a 
study that utilized live cell imaging combined with computational modeling to 
analyze the transcription complex dynamics of rDNA transcription regulation during 
the cell cycle. Using this approach it was demonstrated that activation of rDNA 
transcription in vivo occurs via modulation of the efficiency of PIC assembly i.e., 
through changes in transcription initiation [32]. 
Emerging evidence however, suggests that the elongation step in Pol I transcription is 
important for the overall control of rRNA synthesis rate as well as ensuring efficient 
rRNA processing [33-37]. In contrast to the model of initiation regulation, 
Stefanovsky et al., demonstrated that transcription elongation, regulated through 
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cyclic phosphorylation of UBF, was the dominant event in growth factor regulation of 
the rRNA genes [37]. However, the question of whether transcription is modulated 
primarily at the level of initiation or elongation remains unclear. 
As the various studies on the limiting steps for rRNA synthesis have been carried out 
with diverse cell types and regulatory conditions it is difficult to directly compare the 
data. In this study, using NIH3T3 fibroblasts as a model system, we have indirectly 
determined initiation and elongation rates using a combination of metabolic labelling 
of the 47/45S rRNA, quantitative chromatin immunoprecipitation (qChIP) analysis to 
measure loading of Pol I on the transcribed region of the 47S rRNA genes and 
overexpression of the transcription initiation factor Rrn3 to identify possible rate-
limiting steps for rRNA synthesis under different physiological states.  
Our data demonstrate that rDNA transcription rate can be modulated over a wide 
range in response to acute manipulation of serum levels without changing Pol I 
loading. Thus, serum stimulation modulates Pol I elongation. In contrast, chronic 
serum removal and arrest in G0/G1 was associated with decreased Pol I loading, thus 
impaired initiation. Overexpression of the initiation factor Rrn3 under serum 
starvation conditions led to restored Pol I loading across the 47S rRNA gene to levels 
similar to those observed in exponentially growing cells. This is consistent with the 
model that increased expression of Rrn3 was sufficient to overcome the block in 
transcription initiation observed during extended serum removal. However, Rrn3 
overexpression did not induce rRNA synthesis in either serum starved, serum 
stimulated nor in G0/G1-arrested cells due to an apparent block in elongation. Thus 
our data suggest Pol I elongation to be limiting for efficient rDNA transcription in 
both acutely and chronically serum-deprived cells.  
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 6 
 These data therefore support a model whereby Pol I elongation controls the 
dynamic range of rRNA synthesis output in response to serum modulation.     
Materials and Methods 
Cell culture and cell lines 
NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 
10% fetal bovine serum (FBS) at 37
o
C. Inducible wild type Rrn3 was expressed in 
NIH3T3 cells using GeneSwitch system (Invitrogen). Cells were maintained as above 
in the presence of 50μg/mL hygromycin (Invitrogen) and 100μg/mL zeocin 
(Invitrogen). Rrn3 expression was induced by the addition of mifepristone (MFP, 
Sigma). Cells were made quiescent by serum deprivation in 0.5% bovine serum 
albumin (Sigma) supplemented DMEM and re-fed with DMEM containing 10% FBS.  
Psoralen crosslinking 
Psoralen crosslinking was performed as described in [11, 12]. Briefly, 5 x 10
6 cells 
were scraped in 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 0.5% NP-
40, nuclei were pelleted (1500 rpm, 4C 10 min) and resuspended in (50 mM Tris- 
HCl, pH 8.3, 40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA), and irradiated in the 
presence of 4,5,8'-trimethylpsoralen (Sigma) with a 366-nm UV light box at a 
distance of 6 cm. 200 μg/ml psoralen was added at a 1:20 dilution every 4 min for a 
total irradiation time of 20 min. Genomic DNA was isolated, digested with Sal I, and 
separated on a 0.9% agarose gel, and alkaline Southern blotting was performed. To 
reverse psoralen cross-linking, filters were treated with 254-nm UV rays at 1,875 × 
100 μJ/cm
2
 using a UV cross-linker (Stratalinker 2400; Agilent Technologies). The 
membrane was then hybridized to a purified 
32
P (Amersham)-labeled nick-translated 
rDNA fragment (-167 to +293 nucleotides relative to transcription start site), hybrids 
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visualized by scanning on a PhosphoImager (GE Healthcare), and quantitated using 
ImageQuant (TLv2005.04; GE Healthcare). 
RNA extraction and cDNA synthesis 
Cells were lysed in 4 M guanidine thiocyanate, 25 mM sodium citrate, pH7.0, 0.5% 
sarcosyl, 0.1 M -mercaptoethanol and RNA extracted according to standard 
methods. First-strand cDNA was synthesized using random hexamer primers and 
reverse transcriptase (Invitrogen) as per manufacturer’s protocol. Primer sequences 
are listed in Supplementary Table 1. 
Ribonuclease protection assay 
Ribonuclease protection assays were performed as described in [38]. 400 to 600pg of 
32
P-riboprobes against the +55 to +155 region of the 5`ETS of mouse rDNA and RNA 
samples from equivalent cell numbers were made up in 80% (v/v) deionized 
formamide, 40 mM PIPES pH6.7, 0.4 M NaCl, 1 mM EDTA, denatured at 85°C and 
hybridized at 45°C overnight. Un-hybridized RNA was digested with 10μg RNase A 
(Roche) and 50U RNase T1 (Roche). After denaturation, hybridized RNA was 
separated on a 5% non-denaturing polyacrylamide gel. The gel was dried and 
visualized by scanning on a PhosphorImager (Fuji imaging plate, Type Bas-IIIs, Fuji 
Photo Film). The images were then quantified with ImageQuant (TLv2005.04; GE 
Healthcare).  
Metabolic labelling to measure rRNA synthesis 
As described in [39], cells were cultured in phosphate-free media (Gibco) 1.5h prior 
to the addition of 500 Ci 32P-orthophosphate (MP Biomedicals) for 30min and 
chased for 1h with non-radioactive media. Total RNA was extracted and 5~10 g of 
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RNA was separated on a 1.2% MOPS- (7.2%) formaldehyde agarose gel. The gel was 
dried and visualized by scanning on a phosphor-imaging screen (GE Healthcare), and 
quantitated using ImageQuant (TLv2005.04; GE Healthcare). 
Chromatin immunoprecipitation 
ChIP was performed as described previously [40] using ~10
6
 cells per 
immunoprecipitation. Cells were crosslinked with 0.6% formaldehyde. Sonicated 
DNA (200-400bp), 4 g of purified antibody or 8 l of sera were used per IP. 
Samples were analyzed in triplicate using the FAST SYBR Green dye on the 
StepOnePlus
TM
 real-time PCR (qRT-PCR) system (Applied Biosystems). To calculate 
the percentage of total DNA bound, unprecipitated input samples from each condition 
were used as reference for all qRT-PCR reactions. Primer sequences were reported in 
[11].  
Western blotting 
20-50 g of whole cell lysates (in 0.5 mM EDTA, 20 mM HEPES pH7.9, 2 % SDS), 
were resolved by SDS-PAGE, electrophoretically transferred onto PVDF membranes 
(Millipore), probed with primary and secondary antibodies then analyzed using 
enhanced chemiluminescence (ECL) detection (GE Healthcare).  
S100 protein extracts and immunoprecipitation 
Cells were collected on ice using a cell lifter, pelleted by centrifugation at 5,000rpm 
for 10min (GSA, Sorvall), and washed twice with isotonic buffer (150 mM NaCl, 30 
mM HEPES pH7.9, 1 mM DTT). The cell pellet was weighed, resuspended in 3 times 
its volumes of low salt buffer (10 mM HEPES pH7.9, 1 mM DTT) incubated on ice 
for 15min, then homogenized approximately 20 times using pestle B. 1 volume of 5X 
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buffer A (200 mM HEPES pH7.9, 17.5 mM MgCl2, 0.75 M KCl, 50 % glycerol, 5 
mM DTT) was added and the samples centrifuged at 12,500rpm (SS34, Sorval) for 
1h. The final S100 extracts (2.7 mg) was pre-cleared with Protein-A Agarose (Sigma) 
in 1X buffer A containing 200 mM KCl. Lysates were then incubated with Anti-
FLAG M2 resin (Sigma) in C20/200 buffer (40 mM HEPES pH7.9, 5 mM MgCl2, 0.2 
mM EDTA, 20% glycerol, 200 mM NaCl, 0.1% NP40) for 2h at 4ºC while tumbling. 
Beads were washed four times with C20/200 buffer and elution was performed with 
25 L of 500μg/mL FLAG Peptide (Sigma). 
Antibodies 
The Pol I (RPA194, A43) antibodies were reported in [41]. The Rrn3 antibody was 
kindly provided by Prof. McStay (NUI Galway). We also used the following reagents 
Rrn3 (sc-11805, Santa Cruz), M2 FLAG (F-3165, Sigma), Actin (69-100-1, MP 
Biomedicals) and Tubulin (C-4585, Sigma). Horseradish peroxidase-conjugated 
secondary antibodies were obtained from BioRAD. 
Statistical Analysis 
One-way Analysis of Variance (ANOVA) statistical analyses was performed in 
conjunction with Dunnett’s post-hoc test for multiple comparisons, using the 
GraphPad Prism statistical program (GraphPad Software).    
 
Results  
The average density of Pol I across the transcribed portion of the rRNA gene  (rDNA) 
is the net result of both the initiation and elongation rates. We have determined the in 
vivo relative contribution of rDNA transcription initiation, and elongation rates to 
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rRNA synthesis by correlating changes in Pol I loading with rDNA transcription rates.  
Thus, by way of example, if acute repression of rDNA transcription was the 
consequence of reduced initiation rates, in the absence of changes in elongation, then 
Pol I loading across the transcribed portion of the rDNA repeat should be significantly 
decreased (Fig 1A, schematic 1 versus schematic 2). If both elongation and initiation 
rates were repressed proportionately and concomitantly then Pol I loading would 
remain unchanged (schematic 1 versus schematic 3). Finally, if elongation was 
repressed in the absence of changes in initiation, then Pol I loading would increase 
immediately downstream of the transcription start site (schematic 1 versus schematic 
4) though depending on initial Pol I density, these increases in Pol I loading may not 
be detectable. In this study, we examine the contribution of Pol I transcription 
initiation and elongation to pre-rRNA production mediated by serum stimulation. 
Importantly, we show that serum withdrawal does not alter the relative proportion of 
silent and transcriptionally competent genes (Fig 1B&C) consistent with previous 
studies reporting that growth factor stimulation does not alter the number of active 
rRNA genes [14]. Thus, rRNA synthesis is primarily modulated by regulation of 
transcription initiation and/or elongation rates upon serum withdrawal. 
 
Acute serum withdrawal preferentially targets steps subsequent to rDNA 
transcription initiation. 
We first examined the relationship between Pol I loading and rDNA transcription 
during conditions of acute serum withdrawal (Fig 2) and re-supplementation with 
serum (Fig 3). Removal of serum (-S) from exponentially growing (Exp) NIH3T3 
cells resulted in a ~75% reduction in pre-rRNA gene transcription rates within 3 hours 
(h) as measured by metabolic pulse labelling of rRNA (Fig 2A&B). Inhibition of 
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PI3K signalling (LY: LY294002), but not mTOR (Rapa: rapamycin), caused a similar 
repression of rRNA synthesis, which was maintained for 24h (Fig 2A&B). qChIP 
analysis was used to examine the effect of acute serum withdrawal on the levels of 
Pol I associated with the transcribed region of the 47S rRNA gene. Despite the 75% 
reduction in rDNA transcription at 3h after serum removal, Pol I loading was not 
altered at either the 5’ externally transcribed spacer (ETS1) region or the 28S regions 
of the 47S rRNA gene (Fig 2C&D). This suggests that at 3h both initiation and 
elongation were proportionally and concomitantly repressed by acute serum removal. 
mTOR inhibition by rapamycin treatment caused small reductions (~25%) in rRNA 
synthesis by 30 min that was maintained up to 12h and restored to levels in Exp cells 
by 24h (Fig 2A&B). In contrast, chemical inhibition of PI3K signalling led to a robust 
decrease in rRNA synthesis and Pol I loading at the 5’ETS and 28S regions of the 47S 
rRNA genes in the same time frame suggesting that acute inhibition of PI3K 
preferentially represses Pol I transcription initiation. This further supports the 
essential role of the PI3K/AKT pathway in regulating Pol I transcription specifically 
at the transcription initiation step [39, 42]. 
Re-addition of 10% serum to cells that had been serum starved for 3h reactivated 
rRNA gene transcription with rates returning to levels observed in exponentially 
growing cells by 3h (Fig 3A&B). Pol I occupancy at the 5’ETS and 28S regions was 
unaltered after 3h of serum withdrawal (-S) but increased at 3h and 6h post re-
addition of serum suggesting that upon re-feeding of acutely serum starved cells, 
initiation responds transiently faster or to a greater extent than elongation resulting in 
an apparent accumulation of Pol I on the rDNA (Fig 3C). 
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Changes in Pol I transcription initiation are associated with chronic 
downregulation of rDNA transcription and cell cycle arrest.   
We extended the above studies to examine the relative contribution of initiation and 
elongation to inhibition of Pol I transcription mediated by sustained serum starvation 
(24-36h of serum withdrawal) (Fig 4A). While serum removal for 24h decreased 
rRNA synthesis rates (Fig 2A and Fig 4A&B), the level of repression was only ~20% 
more than that observed in response to acute removal of serum for 3h (Fig 2B). As 
stated above, acute serum withdrawal reduced rRNA synthesis with no change in Pol 
I loading (Fig 2C). However, chronic serum withdrawal was associated with a 
significant reduction in Pol I loading across the rDNA (Fig 2D and Fig 4C).  
We also determined the temporal activation of rDNA transcription and Pol loading 
after serum re-feeding of chronically serum starved NIH3T3 cells. In this case serum 
re-feeding had no effect on rRNA synthesis after 30min or 1h, as measured by 
metabolic labelling (Fig 4D). Induction of rRNA synthesis however, was observed 3h 
after serum addition. Moreover the observed serum-induced increases in rRNA 
synthesis required the PI3K and AKT signalling pathways, as evident by the ability of 
specific inhibitors to prevent the induction of rRNA synthesis (Fig 4D). The 
activation of rRNA synthesis with serum addition also correlated with elevated Pol I 
loading at the 5’ETS and 28S amplicons (Fig 4C&E), first observed at 3h and 
increased steadily thereafter. Notably, the recovery in Pol I loading was slower than 
that observed in acutely serum-starved cells following re-supplementation of serum 
(Fig 3C). These data suggest that initiation rates are limiting upon serum re-feeding of 
chronically serum starved (24h) cells and thus dictate the recovery rate of rDNA 
transcription.  
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Serum starvation of NIH3T3 cells for 24h leads to cell cycle arrest with ~90% of cells 
in the G0/G1 phase of the cell cycle (data not shown). Thus, the down-regulation of 
Pol I transcription initiation associated with chronic serum withdrawal could be a 
consequence of cellular signalling events associated with the G0/G1 cell cycle arrest. 
Alternatively, cellular stress imposed by serum removal can lead to inactivation of 
key Pol I initiation components resulting in reduced transcription initiation. To 
address these possibilities, we examined rRNA synthesis and Pol I loading at the 
rDNA as cells enter the G0/G1 phase independent of any growth factor manipulation. 
Cells were synchronised in G2/M (Fig 5A, top panel) using nocodazole then released 
into G0/G1 by nocodazole washout. Moderate increases in 47S rRNA levels were 
detected 1h after release from the cell cycle block but these were not maximal until 
24h post release (Fig 5A, bottom panel) by which time the cells were exponentially 
growing. Interestingly, Pol I loading at the 5’ETS and 28S regions was detected in 
G2/M cells in the absence of active transcription. After 1h following release from 
mitotic arrest, we observed a reduction in Pol I loading suggesting that it is either 
released from the rDNA or elongates in the absence of further initiation leading to an 
apparent decrease in loading (Fig 5B).  However, after 2h of release Pol I loading at 
the rRNA genes was similar to that observed in the G2/M cells (0h) and remained 
unaltered at 12h but increased further after 24h (Fig 5B) correlating with the slow 
recovery of rRNA synthesis (Fig 5A). This data suggests that Pol I loading and 
transcription initiation are both limiting as the cells enter G0/G1. Thus, the defects 
observed in Pol I transcription initiation following extended serum starvation are 
likely to be caused by mechanisms associated with cell cycle arrest in G0/G1. 
We also examined a second mechanism of cell cycle arrest-mediated repression of 
rDNA transcription; induced by increased cell confluency. We have previously shown 
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that contact inhibition of fibroblasts is characterised by arrest in G0/G1 and a robust 
downregulation of Pol I transcription [43]. At Day 3 (D3) of confluence G0/G1-
arrested NIH3T3 cells, decreased rDNA transcription was detected in the absence of 
changes in Pol I loading at the 5’ETS and 28S regions, suggesting reduced initiation 
and elongation rates (Fig 5C&D). By D5, impaired initiation led to reduced Pol I 
loading and substantial decrease in rRNA synthesis (Fig 5C&D).  
 
Overexpression of Rrn3 and increased Pol I transcription initiation is not 
sufficient to drive 47S rRNA synthesis. 
To further explore whether transcription initiation was rate limiting under chronic 
serum starvation conditions and cell cycle arrest, we examined the effect of artificially 
increasing initiation rates by overexpression of the Pol I transcription initiation factor 
Rrn3. Rrn3 has been proposed as a major regulatory factor that links growth factors, 
nutrients and stress factor signalling to rDNA transcription rates through the 
formation of a transcriptionally competent Pol I complex [26-30, 44-47]. More 
specifically, serine residues 44, 633 and 649 on Rrn3 were shown to be 
phosphorylated by mTOR, ERK and RSK signalling pathways, respectively [28, 29]. 
Serine 44, 633 and 649 substitutions with alanine led to reduced Rrn3 activity and 
impaired Pol I transcription [28, 29]. While, double serine to aspartic acid mutations 
of the 633 and 649 sites mimicked phosphorylation and enhanced 47S rRNA 
synthesis [29]. 
On the other hand, in yeast cells TOR inactivation resulted in proteasome-
dependent degradation of Rrn3p and a strong reduction in Pol I transcription initiation 
[48]. Indeed, we found that serum withdrawal led to significant reduction in Rrn3 
protein abundance within 30min (Fig 6A). In fact, at 12h and 24h of serum 
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withdrawal Rrn3 levels were reduced by approximately 75% compared to levels in 
exponentially growing cells. This suggests that the decrease in Rrn3 protein levels is, 
at least part of the mechanism for chronic serum starvation-mediated reduction in Pol 
I transcription initiation and rRNA synthesis (Fig 2 and Fig 4A-C). We therefore 
established NIH3T3 cells stably expressing inducible FLAG-tagged wild-type Rrn3 
(Fig 6B), and potential gain-of-function and dominant negative phosphorylation 
mutants of Rrn3 (Supplementary Fig 1A) under the control of mifepristone (MFP). 
Western analysis demonstrated a dose dependent induction of expression for the 
FLAG tagged Rrn3 constructs with an increasing concentration of MFP (Fig 6B and 
Supplementary Fig 1A). We performed co-immunoprecipitation experiments and 
validated the incorporation of FLAG-Rrn3 into the Pol I complex (Fig 6C). 
Intriguingly, the potential gain-of-function Rrn3 mutants (S44D, 3D: serine 44, 633 
and 649 mutated to aspartic acid) and the dominant negative Rrn3 mutant 3A (serines 
44, 633 and 649 mutated to alanine) also associated with both Pol I subunits RPA194 
and A43 (data not shown). Moreover, wild-type Rrn3, the 3A and 3D mutants 
reconstituted Pol I transcription in vitro (Supplementary Fig 1B). 
Furthermore, we confirmed the in vivo functionality of the overexpressed Rrn3 
proteins by determining their activity following cycloheximide (CHX) treatment. 
Previous studies reported that nuclear extracts from cells acutely treated with CHX 
were unable to support accurate transcription from the rDNA promoter by Pol I [45]. 
Moreover, transcription was restored by the addition of Rrn3 purified from untreated 
mammalian or insect cells. Thus CHX specifically targets Pol I initiation through 
inactivation of Rrn3, via disrupting Rrn3 phosphorylation and inhibiting its ability to 
associate with Pol I [45].  
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CHX treatment of NIH3T3 cells for 3h reduced rDNA transcription rates, which 
correlated with decreased Pol loading across the transcribed region of the rRNA genes 
(Supplementary Fig 1C and Supplementary Fig 2A&B). Both the repression of rDNA 
transcription and loading of Pol I across the rDNA repeat in response to CHX was 
rescued by over expression of FLAG-Rrn3 (Supplementary Fig 2A&B). Consistent 
with this, FLAG-immunoprecipitations confirmed the incorporation of FLAG-Rrn3 
into the Pol I complex in the presence of CHX (Supplementary Fig 2C). Surprisingly, 
all the Rrn3 mutants examined also rescued Pol I transcription initiation in vivo in the 
presence of CHX (Supplementary Fig 1C). These results suggest that overexpression 
of Rrn3, not its phosphorylation at serine 44, 633 and 649, is sufficient to rescue 
CHX-mediated repression of rDNA transcription. Indeed, we found that CHX 
treatment mediated proteasome degradation of Rrn3, independent of changes in 
mRNA expression levels (Supplementary Fig 2 D&E). We also observed that 
overexpressing FLAG-Rrn3 rescued Rrn3 protein levels following CHX treatment 
(Supplementary Fig 2F). 
Further, qChIP assays using anti-FLAG antibodies demonstrated that over expressed 
FLAG-Rrn3 was significantly enriched at the ETS1 amplicon in exponentially 
growing cells (Fig 6D). While anti-Rrn3 antibodies detected increased enrichment of 
Rrn3 loading under serum starved condition at ETS1 and ETS2 amplicons within the 
5’ETS region in FLAG-Rrn3 expressing cells compared to empty-vector (pGene) 
cells (Fig 6D). However, the levels of Rrn3 loading on the rDNA were similar in both 
exponentially growing pGene and FLAG-Rrn3 expressing cells. This suggests that in 
exponentially growing cells the enrichment of Rrn3 at the rDNA is tightly control and 
cannot be enhanced by overexpressing Rrn3 alone.  
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We also examined the effect of overexpressed Rrn3 on initiation rates and rRNA gene 
transcription in NIH3T3 cells serum starved for 24h. Exogenous FLAG-Rrn3 
mediated a significant 4-fold increase in 5’ETS rRNA transcripts (~ 600-1000 
nucleotides) as measured by ribonuclease protection assays, similar to that observed 
in pGene control cells stimulated with serum for 12h (Fig 7A). In addition FLAG-
Rrn3 mediated increased enrichment in Pol I loading across the rDNA under serum 
starved condition (Fig 7B). However overexpression of Rrn3 failed to increase full-
length 47S rRNA synthesis rates as measured by metabolic labelling (Fig 7C). Thus 
elongation and/or events coupled to elongation, such as processing, remain limiting. 
Therefore, the data demonstrates that although Pol I loading can be artificially 
increased in serum starved cells, post-initiation steps remain rate limiting for rDNA 
transcription. Furthermore, consistent with the observation that Pol I loading across 
the rDNA was not increased in exponentially growing Rrn3 overexpressing cells 
compared to pGene cells (Fig 7B), neither was rRNA synthesis (Supplementary Fig 
3).  
 
Finally we examined whether overexpressing Rrn3 would prevent the downregulation 
of rDNA transcription in NIH3T3 arrested in G0/G1 mediated by cell confluence (Fig 
7D). Our data demonstrate that overexpressing Rrn3 does not rescue the repression of 
rRNA synthesis in confluent G0/G1-cells in the presence of 10% serum. Thus, in 
addition to initiation becoming limiting in confluence-arrested cells (Fig 5C and Fig 
7D), elongation and/or steps coupled to elongation such as processing are also 
limiting for rDNA transcription under these conditions.  
 
Discussion 
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Coordinated regulation of multiple steps including rDNA transcription initiation and 
elongation is required for efficient synthesis of the rRNAs [34, 42, 49]. By using 
qChIP analysis to evaluate Pol I loading onto the rDNA in combination with pulse 
metabolic labelling to measure newly synthesized 47S pre-rRNA, we demonstrated 
that acute serum withdrawal from exponentially growing cells inhibited 47S pre-
rRNA synthesis without changing Pol I loading onto the rDNA. This suggests that 
growth factor signalling is required for transcription elongation and possibly co-
transcriptional processing of rRNA, which is known to be coupled to elongation in 
yeast [36, 50]. Consistent with this finding, enhanced transcription initiation mediated 
by Rrn3 overexpression was not sufficient to promote full length 47S pre-rRNA 
synthesis under serum starvation conditions, despite elevated Pol I loading at the 
rDNA. These findings clearly demonstrate the essential role of post-initiation steps in 
the regulation of rRNA synthesis by growth factors.  Certainly, work in yeast revealed 
a complex interplay between rRNA production, assembly, cleavage, and folding that 
occurs during elongation [36, 51]. Uncovering how elongation is regulated and how it 
is coupled to rRNA assembly will lead to major advances towards understanding the 
mechanisms of rRNA production [49]. 
In contrast, chronic serum starvation led to a reduction in Pol I loading and thus 
transcription initiation. Indeed, we observed a slower recovery in the restoration of 
Pol I loading at the rDNA to levels observed in exponentially growing cells following 
serum re-feeding compared to that observed in acutely serum-starved cells following 
re-supplementation of serum, where elevated Pol I loading indicating faster initiation 
rate was detected (Fig 3C & Fig 4E). Thus, under condition of chronic serum 
starvation, initiation rates dictate the recovery rate of rRNA synthesis. Moreover, 
serum-induced increases in rRNA synthesis required the PI3K and AKT signalling 
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pathways, further supporting an essential role for PI3K/AKT signalling in mediating 
Pol I transcription initiation [39]. This may be due in part to the stabilization/ 
activation of key transcription factors involved in Pol I initiation including Rrn3. 
Indeed, our data demonstrate that serum stimulation prevents Rrn3 protein 
degradation providing a mechanism for growth factor mediated modulation for Pol I 
transcription initiation. G0/G1 confluence-induced cell cycle arrest was also 
associated with a reduction in transcription initiation and elongation. However, 
overexpression of Rrn3 in confluence G0/G1-arrested cells was unable to restore 
rRNA synthesis. Taken together, our data support a model whereby initiation acts as a 
binary on/off switch for rDNA transcription in response to chronic serum starvation 
conditions or cell cycle regulation; whereas steps subsequent to initiation, such as 
elongation, controls the dynamic range of rRNA synthesis output in response to acute 
growth factor modulation.  
Surprisingly, our data demonstrated that wild-type Rrn3 and Rrn3 mutants 
reconstituted Pol I transcription in vitro and rescued rRNA synthesis in vivo in the 
presence of CHX (Supplementary Fig 1 & Supplementary Fig 2A). This was 
unexpected since CHX was suggested to target the phosphorylation of Rrn3 [45]. 
Thus, it is likely that the phosphorylation of the residues used in this study are not 
targeted for inhibition by CHX and/ or the robust overexpression of Rrn3 can 
overcome the requirement for phosphorylation-mediated regulation of 47S rRNA 
synthesis. The latter scenario is plausible since overexpression of wild-type Rrn3 was 
sufficient to increase rRNA synthesis under certain conditions in yeast and Drosophila 
[48, 52]. In our study, however overexpression of Rrn3 enhanced Pol I transcription 
initiation, but it was unable to promote full-length rRNA production most likely 
because elongation or processes coupled to elongation such as processing become 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 20 
limiting. These findings are in marked contrast to a previous study, demonstrating the 
gain-of-function phosphorylation mutants of Rrn3 to enhance 47S rRNA synthesis 
and proliferation rates in HEK293T cells [29]. One possible explanation for the 
discrepancy is that the SV40 large T antigen oncogenic elements expressed in 
HEK293T can help drive Pol I transcription elongation and other steps required for 
efficient rRNA synthesis. On the other hand, we have recently shown that acute 
amino acid removal rapidly inhibited 47S pre-rRNA synthesis and processing without 
changing Pol I loading onto the rDNA in HeLa cervical cancer cells [42]. We further 
demonstrated that in the absence of amino acids, growth factors were unable to 
promote full-length 47S pre-rRNA synthesis despite elevated Pol I loading at the 
rDNA promoter and enhanced Rrn3-Pol I interaction [42]. These findings further 
support a model whereby Pol I initiation and elongation are upregulated 
concomitantly to prevent one or the other process from becoming limiting. Clearly, 
more work is required to identify mechanisms underlying Pol I transcription 
regulation and how these may be hijacked in order to promoter rRNA synthesis 
during cancer progression. 
In contrast, our data supports the concept that under certain physiological situations, 
down regulation of rRNA production can be uncoupled from efficient Pol I initiation 
complex formation. This is an important observation in light of Pol I transcription 
now being considered a promising target for cancer therapy. Indeed, the Pol I 
transcription inhibitor CX-5461 has progressed into phase I clinical trials [9, 53-56]. 
Thus, the identification of distinct mechanisms that control rDNA transcription 
provides the possibility of improving the potency of targeting Pol I transcription. 
While CX-5461 inhibits SL-1 interaction with Pol I and prevents Pol I recruitment to 
the rDNA promoter [56, 57], it is also possible to inhibit Pol I transcription initiation 
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by targeting the Rrn3/Pol I interaction [58]. Furthermore, we have recently 
demonstrated that acute treatment with CX-5461 (1 hour) induces chromatin defects 
at the rDNA associated with depletion of Pol I binding across the transcribed region, 
leading to activation of DNA damage signalling in the absence of global DNA 
damage [57]. Importantly, we reported improved therapeutic efficacy against 
lymphoma in vivo by combining CX-5461 with inhibitors of DNA damage signalling 
[57]. It is therefore likely that targeting Pol I transcription at multiple levels 
simultaneously (e.g., initiation / elongation and or rRNA processing) may further 
improve the efficacy of therapies targeting rDNA transcription. Indeed, we have 
reported that combining CX-5461 with the mTORC1 inhibitor everolimus led to 
enhanced therapeutic efficacy against lymphoma due to inhibition of ribosome 
biogenesis at multiple levels simultaneously [59]. Together these studies support the 
potential for combining CX-5461 with other reported anti-cancer agents that modulate 
post-initiation processes and warrant further pre-clinical investigation. These include 
drugs that inhibit early rRNA processing (camptothecin and flavopiridol), impair late 
rRNA processing (5-fluorouracil)[60] or disrupt Pol I elongation (CX-3543) [61].  
 
Conclusions 
Our data support an important role for post-initiation processes, such as elongation or 
processing, in modulating the dynamic range of rRNA synthesis rate in response to 
acute growth factor modulation. Considering the current interest in targeting Pol I 
transcription in cancer treatment, the field can look forward to the identification of 
novel modulators of Pol I elongation that may serve as new targets for cancer therapy. 
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Figure Legends. 
Figure 1. A) A schematic of altered Pol I occupancy at the rRNA genes as a result of 
modulating transcription initiation and elongation rates. B) The proportion of active to 
silent rDNA is not altered in the absence of serum. Exponentially growing NIH3T3 
cells were cultured in the presence (Exp) or absence of serum (-S) for 24 hours. 
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Nuclei were extracted and irradiated in the presence of ethanol (EtOH cntrl) or 
psoralen. Genomic DNA was isolated and analyzed by Southern blotting for rRNA 
genes as described in [11]. Active rRNA genes have an open chromatin structure that 
is accessible to psoralen, while silent genes are associated with regularly spaced 
nucleosomes thus are inaccessible to psoralen. After psoralen cross-linking, the active 
and inactive rRNA genes can be distinguished by Southern blotting due to differing 
rates of migration. C) Quantitation of psoralen crosslinking data in B. Error bars 
represent mean  standard deviation (SD), n=2.   
Figure 2. A) Acute serum deprivation inhibits 47S rRNA synthesis without affecting 
Pol I loading at the rDNA. A schematic of the experimental protocol is illustrated in 
the top panel. Exponentially growing (Exp) NIH3T3 cells were serum starved (-S) or 
treated in the presence of serum with 30M of the PI3K inhibitor (LY= LY294002) 
(Calbiochem) or 20nM the mTOR inhibitor Rapamycin (Rapa) (Calbiochem) and 
harvested for 
32
P-orthophosphate metabolic labeling experiments at the indicated time 
points (n=2). Cells were labeled for 30mins then chased for 1h with non-radioactive 
media. Equal amount of total RNA were separated in a 1.2% MOPS-formaldehyde 
agarose gel and stained with ethidium bromide as an indication of loading. 
32
P-labeled 
RNAs were visualized using a Phosphoimager. B) Graphs represents quantification of 
the 47S rRNA band using ImageQuant of data as in A. Error bars represent mean  
SD, n=2. C)  schematic of the mouse rRNA gene with the indicated amplicons used 
in qRT-PCR. Core promoter (Pr) element; ETS, external transcribed sequence; 28S, 
28S region; TSS, transcription start site. D) Samples as in A were harvested for qChIP 
assays to examine Pol I binding at the 5’ETS (ETS1 amplicon) and 28S regions of 
rDNA. The % of DNA immunoprecipitated with anti-Pol I or rabbit serum (RS) 
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antibodies was calculated relative to the unprecipitated input control. % of DNA of 
RS controls were subtracted. Error bars represent mean  s.e.m, n=3.  
 
Figure 3. Serum stimulation following acute inhibition of rRNA synthesis mediates 
reactivation of Pol I transcription as well as moderate increases in Pol I loading at the 
rDNA. A) A schematic of the experimental protocol is illustrated in the top panel. 
NIH3T3 cells were serum starved for 3 hours then re-fed with 10% FBS for the 
indicated time points and harvested for 
32
P-orthophosphate metabolic labeling. Three 
independent 
32
P-orthophosphate metabolic labeling experiments were performed as 
described in Fig 2A, visualized using a Phosphoimager. B) Graphs represents 
quantification of data as in A. Error bars represent mean  SD, n=2. C) Samples as in 
A were harvested for ChIP assays to determine Pol I binding at the ETS1 and 28S of 
rDNA as described in Fig 2D. Error bars represent mean  standard error of the mean 
(s.e.m), n=3. 
 
Figure 4. rRNA synthesis is regulated by serum stimulation. A) A schematic of the 
experimental protocol. NIH3T3 cells were made quiescent by serum deprivation for 
24h then either maintained in serum-free media (-S) or stimulated with 10% serum 
(+S) for 12h before harvesting for 
32
P-metabolic labeling of rRNA as described in Fig 
2A. Briefly, cells were labeled for 30mins and chased with non-radioactive media for 
the times indicated. The RNA samples were separated by 1.2% MOPS formaldehyde 
agarose gel and stained with ethidium bromide. 
32
P-labeled RNAs were visualized 
using a Phosphoimager and quantified using ImageQuant. The graph on the right 
panel represent quantification of 47S/45S rRNA levels for the 1h chase samples, n=6, 
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mean ± s.e.m,* p value < 0.05. B) RNA samples as in A were assayed by ribonuclease 
protection assays using a probe for the 5`ETS. A representative phospho-image of 
n=4 is shown. C) Cells treated as in A were harvested for ChIP analysis to determine 
Pol I binding at the indicated regions across the rDNA. ChIP experiments were 
analyzed as described in Fig 2D. Error bars represent Mean  s.e.m, n=3, * p value < 
0.05, *** p value < 0.0001 compared to corresponding serum starved (-S) samples. 
The lower panel is a schematic of the mouse rRNA gene with the indicated amplicons 
used in qRT-PCR. CORE, core promoter (Pr) element; ETS, external transcribed 
spacer; ITS, internal transcribed spacer; 28S, 28S rRNA coding region; T1, terminator 
region; TSS, transcription start site.  D) Inhibition of PI3K and mTOR pathways 
prevents serum mediated 47S rRNA synthesis and correlates with reduced binding of 
Pol I across the rDNA. Schematic of the experimental protocol is shown in the top 
panel. Exponentially growing NIH3T3 cells were serum starved for 24h, pre-treated 
with 30M LY294002, 5M AKT inhibitor (AKTi) or 20nM Rapamycin (Rapa) for 
30mins before addition of serum (+S) for the indicated time points. A representative 
32
P-orthophosphate metabolic labeling of 47S/45S rRNA is shown in the bottom 
panel, n=3. E) Cells as in D were harvested for ChIP assay to determine Pol I binding 
at the ETS1 and 28S regions of rDNA as in Fig 2D. Error bars represent mean ±  
s.e.m, n=2-7, *p value < 0.05, **p value < 0.001 compared to serum starved (-S) 
control.  
 
Figure 5. rRNA synthesis and Pol I loading at rDNA are regulated during cell cycle 
entry/exit. A) NIH3T3 cells were synchronised in G2M by nocodazole (100ng/ml, 
12h), washed twice with PBS then release into fresh media. Cells were harvested at 
the indicated time points, fixed in 90% ethanol, stained with propidium iodide at 50 
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μg/ml in PBS and analyzed using FACSCalibur and Cellquest Pro software (Becton 
Dickinson). The percentage of cells in G0/G1, S and G2/M phases were determined 
using Modfit 3.0 software, n=3 (top panel). Cells as above were harvested for 
32
P-
metabolic labeling of rRNA as described in Fig 2A. A representative 
32
P-
orthophosphate metabolic labeling of 47S/45S rRNA is shown in the bottom panel, 
n=3. B) Cells as in A were harvested for qChIP assay to determine Pol I binding at the 
ETS1 and 28S regions of rDNA as in Fig 2D. Error bars represent mean ±  s.e.m, n=3. 
C) NIH3T3 cells were growing to 100% confluence over a period of 5 days. Samples 
were taken every 24h for cell cycle analysis as in A, n=3 (top panel). A representative 
32
P-orthophosphate metabolic labeling of 47S rRNA is shown in the bottom panel. D) 
Cells as in C were harvested for qChIP assay to determine Pol I binding at the ETS1 
and 28S regions of rDNA as in Fig 2D. Error bars represent mean ± s.e.m, n=4. 
 
Figure 6.  Establishing inducible FLAG-Rrn3 overexpressing NIH3T3 cell lines. A) 
Rrn3 protein levels are regulated by growth stimuli. Exponentially growing NIH3T3 
cells were incubated in serum starvation media for the indicated time points (top 
panel) then analyzed by western blotting for RNN3 and tubulin levels. The results of 
(n=4) were quantitated using ImageQuant, normalized to tubulin levels and 
represented graphically as fold over control (0), Mean  s.e.m. *** p-value < 0.001, 
**p-value < 0.01, *p-value < 0.05 compared to 0h control (bottom panel). B) pGene 
(empty-vector) control and FLAG-Rrn3 NIH3T3 cells were incubated for 12h in the 
presence of increasing mifepristone (MFP) concentrations and analyzed by western 
blotting using anti-FLAG antibody to determine exogenous Rrn3 expression. Actin 
levels were used as loading control. All subsequent experiments were carried out with 
40 pM doses of MFP.  C) Exogenous Rrn3 is incorporated into the Pol I complex in 
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vivo. S100 extracts were immunoprecipitated with anti-FLAG M2 resin. Association 
with Pol I was determined by western analysis using antibodies against RPA194 and 
A43. D) pGene and Rrn3 overexpressing cells were either exponentially growing 
(Exp) in the presence of 40 pM MFP for 12h or serum starved for 12h (-S) before the 
addition of 40 pM MFP for a further 12h. Cells were then harvested for qChIP assays 
using anti-FLAG M2 resin, anti-Rrn3 and RS antibodies. The % of 
immunoprecipitated DNA was calculated relative to the unprecipitated input control. 
For Rrn3 ChIP samples, % of DNA for the RS controls were subtracted. Error bars 
represent mean  s.e.m, n=4.  
 
Figure 7. Overexpression of Rrn3 increases 5’ETS abundance and Pol I loading 
under serum starvation conditions but does not rescue full-length 47S rRNA 
synthesis. A) pGene and FLAG-RRN3 overexpressing NIH3T3 cells were serum 
starved for 12h before the addition of MFP for further 12h.  pGene cells either 
remained in serum-free media (-S) or stimulated with 10% serum (+S) for 12h, while 
FLAG-Rrn3 overexpressing remained in serum free media before harvesting for 
ribonuclease protection assays as described in Fig 4B. Graph (bottom panel) 
represents quantification of 5’ETS abundance relative to control (0 pGene) as in A 
using ImageQuant n=4, mean  sem, *p value < 0.05 compared to pGene (-S) control. 
B) Cells as in A were harvested for qChIP assay to determine Pol I binding at the 
rDNA as in Fig 2D. Error bars represent mean ± s.e.m, n=3, *p value < 0.05. C) Cells 
treated as in A were analyzed by 
32
P-orthophosphate metabolic labeling to determine 
47S/45S rRNA as in Fig 2A. A representative image of n=3. D) pGene and Rrn3 
overexpressing cells were grown to 100% confluence and analyzed by 
32
P-
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orthophosphate metabolic labeling to determine 47S/45S rRNA as in Fig 2A. A 
representative image of n=2. 
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Abbreviation list 
 
 
+S: With serum; -S: Without serum; CHX: cycloheximide; DMEM: Dulbecco’s 
modified Eagle’s medium; ECL: Enhanced chemiluminescence; ETS: Externally 
transcribed spacer; Exp: Exponentially growing cells; FBS: Fetal bovine serum; h: 
Hour; LY: LY294002; MFP: Mifepristone; PI3K: Phosphatidylinositol-3-Kinase; 
PIC: Preinitiation complex; Pol I: RNA polymerase I; qChIP: Quantitative chromatin 
immunoprecipitation; qRT-PCR: Quantitative real-time PCR; rapa: Rapamycin; 
rDNA: Ribosomal RNA gene; rRNA: Ribosomal RNA; SD: standard deviation; 
s.e.m: Standard error of the mean; SL-I: Selectivity factor 1; UBF: Upstream binding 
factor. 
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Paper Highlights: 
 
1) Acute serum withdrawal from cells does not alter Pol I loading onto rDNA 
 
2) Acute serum stimuli modulates Pol I transcription at post-initiation steps 
 
3) Cell cycle arrest is associated with repression of Pol I transcription initiation and 
elongation  
 
4) Rrn3 overexpression does not rescue rRNA synthesis when Pol I elongation is 
limiting 
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